683 Capital Management LLC Acquires 1,065,000 Shares of InflaRx N.V. $IFRX

683 Capital Management LLC lifted its holdings in InflaRx N.V. (NASDAQ:IFRX) by 47.3% during the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 3,315,000 shares of the company’s stock after buying an additional 1,065,000 shares during the period. 683 Capital Management LLC owned about 4.94% of InflaRx worth $3,348,000 at the end of the most recent reporting period.

Other large investors have also recently made changes to their positions in the company. Cubist Systematic Strategies LLC increased its holdings in shares of InflaRx by 33.9% in the 1st quarter. Cubist Systematic Strategies LLC now owns 30,053 shares of the company’s stock worth $31,000 after buying an additional 7,616 shares during the last quarter. HRT Financial LP bought a new stake in shares of InflaRx in the 4th quarter worth about $47,000. Concurrent Investment Advisors LLC boosted its stake in shares of InflaRx by 56.9% during the 4th quarter. Concurrent Investment Advisors LLC now owns 52,951 shares of the company’s stock worth $53,000 after purchasing an additional 19,200 shares during the period. Insigneo Advisory Services LLC purchased a new position in shares of InflaRx during the 4th quarter worth about $61,000. Finally, DCF Advisers LLC purchased a new position in shares of InflaRx during the 4th quarter worth about $160,000. 42.39% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

A number of equities analysts recently commented on IFRX shares. Wall Street Zen raised shares of InflaRx from a “sell” rating to a “hold” rating in a research note on Saturday, May 9th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of InflaRx in a research note on Friday, March 27th. Oppenheimer started coverage on shares of InflaRx in a research note on Friday, April 24th. They set an “outperform” rating and a $5.00 price target for the company. Cantor Fitzgerald lifted their price target on shares of InflaRx from $2.00 to $4.00 and gave the stock an “overweight” rating in a research note on Monday, May 11th. Finally, HC Wainwright lifted their price target on shares of InflaRx from $6.00 to $8.00 and gave the stock a “buy” rating in a research note on Monday, May 11th. One equities research analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, InflaRx has an average rating of “Moderate Buy” and an average price target of $7.00.

InflaRx Price Performance

Shares of IFRX opened at $1.82 on Thursday. InflaRx N.V. has a 1-year low of $0.74 and a 1-year high of $2.95. The company has a 50-day moving average of $1.93 and a 200 day moving average of $1.31. The firm has a market capitalization of $131.57 million, a price-to-earnings ratio of -2.56 and a beta of 2.42.

InflaRx (NASDAQ:IFRX) last announced its quarterly earnings data on Thursday, May 7th. The company reported ($0.09) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.17) by $0.08. On average, equities analysts anticipate that InflaRx N.V. will post -0.4 earnings per share for the current fiscal year.

About InflaRx

InflaRx N.V. is a clinical‐stage biopharmaceutical company focused on the discovery, development and commercialization of novel therapies targeting the complement system, with an emphasis on the complement‐1a (C5a) pathway. The company’s lead product candidate, vilobelimab (IFX‐1), is a monoclonal antibody designed to selectively inhibit C5a, a potent pro‐inflammatory peptide implicated in a range of autoimmune and inflammatory diseases. InflaRx seeks to address high‐unmet medical needs by advancing treatments for conditions such as hidradenitis suppurativa, pyoderma gangrenosum and other rare and severe inflammatory disorders.

Vilobelimab has been evaluated in multiple Phase II trials, demonstrating proof of concept in reducing key inflammatory markers and improving clinical outcomes.